CaHA
Hydroxyapatite (CaHA)
A core foundational material for bone repair, aesthetic medicine, scientific research and development, and other high-end application scenarios.
View DetailsNanjing Junzhuo Biotechnology Co., Ltd.Advancing Biomaterials with Precision
Nanjing Junzhuo Biotechnology Co., Ltd. specializes in the R&D, manufacturing, and application support of advanced hydroxyapatite and bioceramic materials. We are committed to delivering highly stable and specialized material solutions for orthopedic reconstruction, medical aesthetic injectables, surface coatings, and translational research.
HydroxyapatiteCaHA Microspheresβ-TCPCalcium SilicateRegenerative Biomaterials
Products
β-TCP
Beta Tricalcium Phosphate (β-TCP)
Beta tricalcium phosphate (β-TCP) is a high-performance bioceramic material with biomimetic mineral characteristics.
View DetailsNEW
New Materials (BCP, CS, CSH)
Centered on material directions such as biphasic calcium phosphate, calcium silicate, and calcium sulfate hemihydrate, we continue to advance the in-depth development of new bioceramic materials.
View DetailsOEM
Custom Development
Across key dimensions such as particle size distribution, morphology, packaging format, and application documentation, we support custom development from requirement communication and sample validation to project onboarding.
View DetailsAbout Junzhuo
Nanjing Junzhuo Biotechnology Co., Ltd. focuses on the research, production, and custom development of high-end biomaterials, providing professional material solutions for customers worldwide.
About Junzhuo
News Center
The latest updates on company developments, technical articles, and industry content.
What SEM Images Can—and Cannot—Show About CaHA Microspheres
A technical review of JCD market-sample SEM papers, clarifying what CaHA microsphere images can and cannot support and where higher-level evidence is still needed.
Aphranel® Receives EU MDR Certification: A New Milestone for China’s CaHA Filler Market
On June 5, 2026, Aphranel® announced that its MagiCCrystal CaHA Filler had received EU MDR certification, alongside the launch of Arc™ and cumulative commercial deliveries exceeding 150,000 syringes. This marks a noteworthy milestone for China’s CaHA filler market.
GLP-1 Weight Loss: Bringing Facial Volume Deficits Back Into Focus
An analysis of midfacial volume, skin quality, and HA-CaHA composite injectables post-GLP-1 medical weight loss, drawing on AMWC 2026 posters, ASJ Open Forum publications, Reuters reports, and Teoxane publications.